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PURPOSE. Insulin-like growth factor-I receptor (IGF-IR) signaling mediates retinal growth and
survival and its failure may contribute to aggravate diabetic retinopathy (DR). Protein tyrosine
phosphatase 1B (PTP1B) negatively modulates IGF-IR signaling, but its involvement in
inflammation during DR remains unknown. We investigated whether PTP1B participates in
the cross-talk between proinflammatory signaling pathways and IGF-IR–mediated signaling in
the retina.
METHODS. 661W photoreceptors or mouse retinal explants were treated with TNFa, IL6, and
IL1b. Insulin-like growth factor-I receptor signaling cascade was evaluated in the absence or
presence of PTP1B. db/db mice were used to test a PTP1B inhibitor in retinal gliosis.
RESULTS. 661W retinal cells and retinal explants responded to IGF-I by inducing IGF-IR tyrosine
(13-fold) and Akt phosphorylations (7- and 3-fold for serine 473 and threonine 308,
respectively). Cytokines triggered early activation of stress kinases (c-jun [NH2] terminal
kinase [JNK] and p38 MAPK), resulting in insulin receptor substrate 1 (IRS1) serine 307
phosphorylation that precedes its degradation. Pretreatment of 661W cells or retinal explants
with cytokines upregulated PTP1B protein levels (1.45- and 4.5-fold, respectively), induced
IRS1 degradation and decreased IGF-I–mediated IGF-IR/Akt phosphorylation. Silencing or
deficiency in PTP1B ameliorated the negative effects of cytokines on IGF-IR signaling.
Cytokines increased glial fibrillary acidic protein (GFAP) expression in retinal explants by 4.5-
fold, this response being reduced by 2-fold with a PTP1B inhibitor. Protein tyrosine
phosphatase 1B protein levels increased by 3-fold in retinas from db/db mice and its
inhibition reduced gliosis.
CONCLUSIONS. Targeting PTP1B might be useful for modulating IGF-I effects in retinal cells
during DR.
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Diabetic retinopathy (DR) is a major cause of blindnessglobally and a leading cause of legal blindness in the
working age population of the developing world.1,2 Diabetes
affects the entire neurovascular unit of the retina, with gradual
neurodegeneration, gliosis, neuroinflammation, compromise of
the vascular blood–retinal barrier, edema, angiogenesis, and
eventual fibrosis. Although neurodegeneration and inflamma-
tion have been implicated in the etiology of DR,3–5 diagnosis
and treatment of this disease are mainly focused on the vascular
abnormalities that ultimately occur.
Type 2 diabetes mellitus (T2DM) is recognized as a low
grade chronic inflammatory disease in which initially the
infiltration of immune cells in adipose tissue generates a
systemic proinflammatory milieu that negatively interferes with
insulin signaling.6 Moreover, prolonged metabolic stress leads
to a chronic state of overactivation of immune cells of the
central nervous system (CNS), leading to neuroinflammation.7
Therefore, adipose-derived inflammatory mediators could be an
important addition to local cytokines produced by CNS-resident
microglia in boosting brain inflammation. A number of
metabolic or molecular abnormalities associated to inflamma-
tion have been detected in retinas of diabetic animals, patients,
or in retinal cells exposed to elevated concentrations of
glucose8 raising the hypothesis that these defects might reflect
an imbalance between pro- and anti-inflammatory cytokine
expression.9–11
Insulin and insulin-like growth factor-I receptors (IR and
IGF-IR, respectively) belong to the tyrosine kinase receptor
superfamily. Activation of both receptors stimulates tyrosine
phosphorylation of insulin receptor substrates (IRS) that act as
docking proteins engaging the receptors with intracellular
signaling pathways. Among these, activation of phosphatidyli-
nositol (PI) 3-kinase/Akt is essential for the cell survival.12,13
The IGF-I/IGF-IR system is expressed in retinal neurons14,15 and
IGF-I is a proliferation and differentiation factor for the neural
retina.16
Recent evidences support the involvement of two recog-
nized factors linking T2DM with neurodegeneration; the
elevation of proinflammatory cytokines and the onset of
insulin/IGF-I resistance.17 In T2DM, proinflammatory cytokines
such as TNFa trigger phosphorylation of insulin receptor
substrate 1 (IRS1) at serine 307 by stress kinases,18 which
Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
iovs.arvojournals.org j ISSN: 1552-5783 8031
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/934740/ on 08/22/2017
disrupts its interaction with the IR and blocks the intracellular
actions of insulin in peripheral tissues. Likewise, excess of
peripheral proinflammatory mediators, some of which can
cross the blood–brain barrier, may trigger insulin/IGF-I
resistance in the CNS, thereby weakening the neuroprotective
signaling mediated by these molecules and this effect can
contribute to the onset of neurodegenerative diseases.17 In this
regard, it been demonstrated that IGF-I elicits neuroprotective
effects in neurons exposed to several stressors including
hypoxia-ischemia.19
Protein tyrosine phosphatase 1B (PTP1B), an ubiquitously
expressed phosphatase, has emerged as a relevant modulator
of IR and IGF-IR signaling pathways by its ability to
dephosphorylate tyrosines within the catalytic domain in both
receptors.20–22 In mice, deletion of the ptpn1 gene increased
insulin sensitivity in liver and skeletal muscle and protects
against obesity.23,24 In the retina, PTP1B is expressed in rod
photoreceptor cells25 and also targets IGF-IR–mediated signal-
ing.26 However, the modulation of the signaling pathways
activated by the IGF-IR and the impact of PTP1B inhibition in
the presence of a proinflammatory environment in the retina
remains unknown and is the aim of the present study.
MATERIALS AND METHODS
Reagents
Fetal bovine serum (FBS) and culture media were from
Invitrogen (Grand Island, NY, USA). Bovine serum albumin
(BSA) was purchased from Sigma-Aldrich Corp. (St. Louis, MO,
USA). IGF-I (human recombinant), IL1b, IL6, and TNFa were
purchased from Preprotech (London, UK). Noncompetitive
PTP1B inhibitor was 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-eth-
yl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-
amide (Catalog number 539741; Calbiochem, Darmstadt,
Germany). Bradford reagent, acrylamide, immunoblot poly-
vinylidene difluoride (PVDF) membranes and chemilumines-
cent horseradish peroxidase (HRP) substrate were purchased
from Bio-Rad (Madrid, Spain).
Antibodies
Anti–IGF-IR (sc-713), anti–phospho-Akt1/2/3 (Ser473; sc-7985-
R), anti–phospho-Akt1/2/3 (Thr308; sc-166646-R), anti-Akt1/2/
3 (sc-8312), anti-JNK (sc-571), and anti-phospho p38 MAPK
(Thr 180/Tyr182; sc-17852-R) antibodies were from Santa Cruz
Biotechnology (Palo Alto, CA, USA). Anti-phospho IRS1 (Ser
307; 07-247), anti-p85a (06-195) and anti-PTP1B (05-1087,
recognizes cleavaged PTP1B) and anti-PTP1B (07-088) antibod-
ies were purchased from Merk-Millipore (Merck KGaA,
Darmstadt, Germany). Anti–phospho-IGF-IR b (Tyr1135/1136;
#3024), anti-phospho Akt (Ser473; #9272), anti-phospho JNK
(Thr183/Tyr185) (#4668), and anti-phospho p38 MAPK
(#9212) antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA). Anti–a-tubulin (T-0198)
antibody was from Sigma-Aldrich Corp. and anti–glial fibrillary
acidic protein (GFAP) antibody (z0334) was obtained from
DAKO (Glostrup, Denmark).
Cell Culture
The 661W cell line derived from immortalized cone photore-
ceptors,27 provided by Muayyad Al-Ubaidi (University of
Oklahoma, Norman, OK, USA), was maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
(vol/vol) heat-inactivated FBS. For experiments, 661W cells
were seeded at 753103 cells/well in six-well plates. Confluent
cells were grown in serum-free medium in the absence or
presence of cytokines (CK; TNFa, IL6, and IL1b; 20 ng/mL
each) for several time periods. In some experiments, after 24
hours of incubation with cytokines, IGF-I (10 nM) was added
for the last 15 minutes.
Retinal Explants
Ex vivo assays were performed with retinas from 10-week-old
male C57BL/6 mice, db/þ and db/db mice, purchased from
Charles River Laboratories (Charles River, Barcelona, Spain), or
with age-matched PTP1B-deficient (PTP1B/) mice.26 Mice
were maintained in light/dark (12-hours light/12-hours dark),
temperature (228C), and humidity-controlled rooms, and fed ad
libitum with free access to water. All animal experimentation
followed recommendations of the Federation of European
Laboratory Animal Science Associations (FELASA) on health
monitoring in accordance with the regulations of the
Association for Research in Vision and Ophthalmology (ARVO).
Animals were killed by cervical dislocation and eyes were
enucleated. The lens, anterior segment, vitreous body, retinal
pigment epithelium, and sclera were removed and the retina
was cultured in R16 medium (provided by PA Ekstrom, Lund
University, Sweden) with no additional serum. Retinas were
stimulated with cytokines (CK; TNFa, IL6, and IL1b; 20 ng/mL
each) and/or IGF-I (20 nM) at the time periods indicated in the
figure legends.
Quantitative Real-Time PCR Analysis
Total RNA was extracted with Trizol (Fisher Scientific-USA,
Waltham, MA, USA) and reverse transcribed using High-
Capacity cDNA Reverse Transcription Kit (ThermoFisher
Scientific, Madrid, Spain). Quantitative real-time PCR (qPCR)
was performed with an ABI 7900 sequence detector (Thermo-
Fisher Scientific). The primer-probe sets for mouse ptpn1 and
18s were purchased as predesigned TaqMan gene expression
(Life Technologies; catalog numbers Mm_00448427_m1 and
Mm 04277571, respectively). The PCR cycles were 958C for 10
minutes, 40 cycles at 958C for 15 seconds and 608C for 60
seconds following the manufacturer’s instructions (Applied
Biosystems, Madrid, Spain).
Transient Transfection With siRNA
siRNA oligonucleotides were synthesized by Dharmacon RNAi
Technologies (Fisher Scientific-USA). Targeted sequences for
ptpn1 were: 5 0GGAGAAAGGCUCGUUAAAA30; 50GACCACA
GUCGGAUUAAAU30; 50GGUUUGAAGUUGACACUAA30; 50UCG
CGAAGCUUCCUAAGAA30 (siGENOME SMART pool, mouse
ptpn1). 661W cells and retinal explants were transfected with
scrambled (siGENOME RISC-free Control siRNA; catalog
number D-001220-01; Fisher Scientific-USA) or PTP1B siRNAs
at 25 nM concentration following manufacturer’s instructions.
After 36 hours, transfected cells and retinal explants were
treated with cytokines (CK; 20 ng/mL) for 24 hours, serum-
starved for 2 hours and further stimulated with IGF-I (10 nM)
for 15 minutes. Scrambled or PTP1B siRNA oligos were present
during treatment with cytokines and IGF-I.
Western Blotting
Proteins were resolved using denaturing SDS-PAGE, and
transferred to PVDF membranes (Bio-Rad).26 Membranes were
blocked using 5% nonfat dried milk or 3% BSA in 10 mM Tris-
HCl, 150 mM NaCl, pH 7.5 (TBS), and incubated overnight
with antibodies in 0.05% Tween-20-TBS. Immunoreactive
bands were visualized using the enhanced chemioluminis-
cence reagent (Bio-Rad). Levels of phosphorylated proteins
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(pIGF-IR and pAkt) were normalized by levels of correspond-
ing total (IGF-IR and Akt) proteins that were used as loading
controls. These results are expressed as fold change of IGF-I
stimulation related to each basal. Levels of PTP1B were
normalized by a-tubulin.
PTP1B Enzymatic Activity
PTP1B phosphatase activity was determined by measuring
phosphate release using a synthetic monophosphotyrosyl-
containing peptide and the malachite green assay (Ref. 17-
125; Millipore) as described.28
Histologic Analysis and Immunofluorescence
Retinal explants were fixed in 4% paraformaldehyde for 8
hours, washed in TBS containing 0.1% (wt/vol) BSA and 0.1%
(vol/vol) Triton X-100 (this buffer was used for all subsequent
washes) and blocked and permeated for 2 hours in TBS
containing 3% (wt/vol) BSA and 1% (vol/vol) Triton X-100. The
samples were incubated overnight in a humid chamber at 48C
with rabbit anti-GFAP antibody in blocking solution. Retinal
explants were washed and incubated for 90 minutes with anti-
rabbit immunoglobulin antibody conjugated to Alexa 488
(Molecular Probes, Eugene, OR, USA), washed, and mounted
with mounting medium (Fluoromount G). Staining was
observed with a laser confocal microscope LSM710 (Carl Zeiss
Microscopy GmbH, Go¨ttingen, Germany). For quantification of
GFAP immunostaining, mean fluorescence density was mea-
sured in five fields per retina using the ImageJ software (http://
imagej.nih.gov/ij/; provided in the public domain by the
National Institutes of Health, Bethesda, MD, USA).
Statistical Analysis
Densitometry of the Western blots was performed using the
ImageJ program. Values in all graphs represented the mean 6
SEM. Statistical tests were performed using SPSS 21.0 for
Windows (SPSS, Inc., IBM, Armonk, NY, USA). Data were
analyzed by 1- or 2-way ANOVA followed by Bonferroni t-test or
by paired t-test when comparisons were among two groups.
Differences were considered significant at P  0.05.
FIGURE 1. Insulin-like growth factor-IR–mediated Akt signaling in 661W retinal cells. Confluent 661W cells were serum-starved for 2 hours and then
stimulated with various doses of IGF-I for 15 minutes. Protein extracts (30 lg) were separated by SDS-PAGE and analyzed by Western blot with the
anti-phospho IGF-IR (Tyr1135/1136), anti–IGF-IR, anti-phospho Akt (Ser473), anti-phospho Akt (Thr308), and anti-Akt antibodies. (A)
Representative autoradiograms are shown (n¼ 3 independent experiments). (B) The blots were quantitated by scanning densitometry. Levels of
phosphorylated IGF-IR and Akt were normalized by their corresponding levels of total IGF-I or Akt protein, respectively, that were used as loading
control. Results are expressed as fold increase of IGF-I stimulation and are means 6 SEM. Data were analyzed by 1-way ANOVA followed by
Bonferroni t-test. Comparisons were *†‡P  0.05 IGF-I stimulation versus their corresponding nonstimulated basal (B).
PTP1B in Retinal Inflammation IOVS j December 2015 j Vol. 56 j No. 13 j 8033
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/934740/ on 08/22/2017
RESULTS
IGF-I Induces Phosphorylation of the IGF-IR and
Akt in Retinal Cells
Insulin-like growth factor-I and its receptor (IGF-IR) are
expressed in the inner retina,14,15 and retinal microvascular
cells produce,29 and respond to IGF-I in vitro.30 Because
activation of the IGF-IR/Akt signaling cascade protects
mammalian cell types against death signals,31 we characterized
the activation of this pathway in 661W cells that expressed
cone photoreceptor markers.27 As shown in Figures 1A and 1B,
in 661W photoreceptors phosphorylation of the IGF-IR at
tyrosines 1135/1136 within the catalytic domain and Akt at
threonine 308 occurred in a dose-dependent manner; being
maximal effect elicited at 10 nM (13-fold for IGF-IR tyrosine
phosphorylation and 7-fold for Akt threonine 308 phosphor-
ylation). Maximal phosphorylation of Akt at serine 473 (3-fold),
which was mediated by the mTORC2 complex,32 was detected
at 0.1 nM. These results indicate that 661W retinal cells
respond to IGF-I and agree with the activation of IGF-IR/Akt
signaling by IGF-I in retinal explants.26
Retinal Cells Respond to Proinflammatory
Cytokines by the Activation of Stress Kinases
Because proinflammatory cytokines were components of the
diabetic milieu in the retina,33 we inspected the sensitivity of
retinal cells to the activation of stress kinases in response to
proinflammatory cytokines. A mixture of proinflammatory
cytokines (TNFa, IL6, and IL1b) was used to stimulate 661W
FIGURE 2. A combination of proinflammatory cytokines (CK) induced the activation of stress kinases and the phosphorylation of IRS1 at serine 307
in retinal cells. (A) 661W photoreceptors and (C) mouse retinal explants were stimulated with a combination of proinflammatory cytokines
containing TNFa, IL6, and IL1b (CK; 20 ng/mL each) at the indicated time-periods. Protein extracts (50 lg) were separated by SDS-PAGE and the
phosphorylation of IRS1 (Ser307), JNK (Thr183/Tyr185), and p38 MAPK (Thr180/Tyr182) was analyzed by Western blot with the corresponding
antibodies. Total levels of IRS1, JNK, and p38 MAPK were also analyzed. Representative autoradiograms are shown (n ¼ 3 independent
experiments). In (B) and (D) the results are means 6 SEM. Data were analyzed by 1-way ANOVA followed by Bonferroni t-test. Comparisons were
*†‡P  0.05 cytokines (CK) versus their corresponding nonstimulated basal (B).
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FIGURE 3. Proinflammatory cytokines activated signaling pathways that negatively modulated IGF-IR–mediated signaling. 661W cells (A–C) and
retinal explants (D, E) were treated with cytokines (CK; 20 ng/mL) for 24 hours, serum-starved for 2 hours, and further stimulated with IGF-I (I; 10
nM) for 15 minutes (661W retinal cells) or IGF-I (I; 20 nM) for 30 minutes (retinal explants). In (B) (661W cells) and (E) (retinal explants) the
treatment was 24 hours with cytokines. Protein extracts (50 lg) were separated by SDS-PAGE and analyzed by Western blot with antibodies against
phospho–IGF-IR (Tyr1135/1366), IGF-IR, phospho-Akt (Ser473), phospho-Akt (Thr308), Akt, IRS1, and a-tubulin. Representative autoradiograms are
shown (n ¼ 6 independent experiments). The blots were quantitated by scanning densitometry. Levels of phosphorylated proteins (pIGF-IR and
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cells and phosphorylations of c-jun (NH2) terminal kinase
(JNK) and p38 mitogen-activated protein kinase (MAPK) were
analyzed. As shown in Figures 2A and 2B, phosphorylation of
JNK and p38 MAPK was very rapid and peaked at 15 and 30
minutes, respectively, after addition of cytokines. A 14- and 2.5-
fold increase in JNK and p38 MAPK phosphorylations,
respectively, were found at these time periods.
We also analyzed these responses in the whole retina using
retinal explants that preserved the sensitivity to extracellular
stimuli26 and found maximal JNK (4-fold) and p38 MAPK (12-
fold) phosphorylations at 1 and 2 hours, respectively (Figs. 2C,
2D).
Serine phosphorylation of IRS1, an immediate downstream
target of the IGF-IR, precedes its ubiquitination and proteaso-
mal degradation.34,35 Among potential IRS1 serine kinases, JNK
has been extensively studied in insulin resistant states.36
Treatment with cytokines increased IRS1 serine 307 phos-
phorylation in 661W cells by 3.5-fold and, importantly, similar
effect occurred in retinal explants where cytokines increased
this response by 15-fold (Figs. 2A–D).
Proinflammatory Cytokines Negatively Interfered
With IGF-IR/Akt Signaling in Retinal Cells
Because proinflammatory cytokines trigger early and long-term
signaling pathways that negatively modulate IGF-IR–mediated
signaling,37 we analyzed this cross-talk in retinal cells. 661W
cells were pretreated with cytokines for 24 hours, serum-
starved for 2 hours, and further stimulated with IGF-I (10 nM)
for 15 minutes. This prolonged treatment with cytokines did
not induce death of 661W cells (results not shown). Insulin-
like growth factor-I–induced IGF-IR tyrosine phosphorylation
decreased by 6.5-fold in 661W cells pretreated with cytokines
as compared with nonpretreated cells (CKI versus I; Fig. 3A).
Downstream the IGF-IR, IRS1 levels significantly decreased
(0.5-fold) in the presence of cytokines, reflecting its proteoso-
mal degradation (Fig. 3B). Likewise, the response to IGF-I in
the phosphorylation of Akt (threonine 308 and serine 473) was
decreased by 7.5- and 3.5-fold, respectively, in cells pretreated
with cytokines compared with nonpretreated cells (CKI versus
I; Fig. 3C).
To demonstrate the physiological relevance of these data,
mouse retinas were incubated ex vivo with cytokines for 24
hours and then stimulated with IGF-I (20 nM) for 30 minutes.
Cell death was not detected in retinal explants treated with
cytokines (results not shown). Pretreatment with cytokines
reduced the response to IGF-I in inducing IGF-IR tyrosine
phosphorylation at basal levels (CKI versus I) and also
reduced by 1.75 fold Akt phosphorylation at serine 473 as
compared with explants that did not receive proinflammatory
stimuli (CKI versus I; Fig. 3D). Notably, in retinal explants the
treatment with cytokines increased basal Akt phosphoryla-
tion by 5.5 fold (CK versus B), but this response was not
further increased by IGF-I stimulation, reflecting the lack of
sensitivity to IGF-I. Degradation of IRS1 was found in retinal
explants cultured in the presence of cytokines compared
with the basal condition (0.5-fold decrease in CK versus B;
Fig. 3E).
Modulation of PTP1B Expression and Enzymatic
Activity in Retinal Photoreceptors and Retinal
Explants Under Proinflammatory Conditions
We have demonstrated that PTP1B is elevated in the retina of
diabetic mice and the modulation of IGF-IR tyrosine phosphor-
ylation by this phosphatase in retinal explants.26 Based on that,
we analyzed the effect of the proinflammatory milieu on
PTP1B expression in photoreceptors. As Figure 4A showed,
PTP1B mRNA was elevated by 2.5-fold in 661W cells treated
with cytokines. Moreover, cytokines induced the cleavage of
the protein with a similar pattern reported in platelets38 and
also increased PTP1B protein levels by 1.5-fold (Fig. 4B) and
enzymatic activity by 2-fold reflecting the activation of the
phosphatase activity associated to this cleavage38 (Fig. 4C). In
agreement with data in peripheral tissues,39 PTP1B mRNA and
protein expression were also increased by 3.8- and 4.5-fold,
respectively, in retinal explants cultured with cytokines (Figs.
4D, 4E).
Reduction of PTP1B in Retinal Cells Protected
Against Inflammation-Mediated Inhibition of IGF-
IR Signaling
We have demonstrated that PTP1B inhibition restored hepatic
insulin sensitivity in several in vivo models of insulin
resistance.28,40,41 On that basis, we investigated the effect of
cytokines on IGF-IR–mediated signaling in retinal cells with
reduced PTP1B expression using siRNA. Protein tyrosine
phosphatase 1B protein content was decreased by almost
90% in 661W cells transfected with PTP1B siRNA (Fig. 5A).
Then, we analyzed IGF-IR–mediated signaling in the presence
of cytokines and we found that PTP1B silencing maintained
IGF-IR tyrosine phosphorylation and Akt (serine 473) phos-
phorylation in the presence of cytokines compared with the
reduced responses of the control (scrambled) condition. In
cells transfected with scrambled siRNA, IGF-I–mediated IGF-IR
phosphorylation was reduced by 4-fold when they were
pretreated with cytokines (CKI SC versus I SC; Figs. 5B, 5C).
Moreover, in cells transfected with PTP1B siRNA, IGF-I–
mediated IGF-IR phosphorylation in the presence of cytokines
was 5-fold higher than the response of this condition in the
scrambled siRNA treatment (CKI siRNA PTP1B versus CKI SC).
Regarding Akt, IGF-I–mediated phosphorylation at serine 473
was reduced by 7.6-fold when cells were pretreated with
cytokines (CKI SC versus I SC). By contrast, in cells transfected
with PTP1B siRNA this response was 8.2-fold increase
compared with this condition in the scrambled siRNA
treatment (CKI siRNA PTP1B versus CKI SC).
In mouse retinal explants, PTP1B siRNA efficiently reduced
almost 70% PTP1B protein levels (Fig. 5D) and improved IGF-
IR/Akt-mediated signaling in the presence of cytokines. Insulin-
like growth factor-I–mediated Akt phosphorylation at serine
473 was reduced by 3.6-fold when retinal explants were
pretreated with cytokines (CKI SC versus I SC; Figs. 5E, 5F). In
retinal explants transfected with PTP1B siRNA, IGF-I–mediated
Akt serine 473 phosphorylation in the presence of cytokines
pAkt) were normalized by levels of their corresponding total IGF-IR and Akt protein that were used as loading controls. These results are expressed
as fold change of IGF-I stimulation related to each basal. Alpha-tubulin was used as a loading control for IRS1. The results are means 6 SEM. Data
were analyzed by 1- or 2-way ANOVA followed by Bonferroni t-test. In (A, C, D) comparisons were *P  0.05 IGF-I (I) versus nonstimulated basal (B);
†P  0.05 cytokines plus IGF-I (CKI) versus IGF-I (I). In (B) and (E) results are means 6 SEM. Data were analyzed by paired t-test. Comparisons were
*P  0.05 cytokines (CK) versus nonstimulated basal (B).
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FIGURE 4. Protein tyrosine phosphatase 1B expression is upregulated in retinal cells and retinal explants cultured under proinflammatory conditions.
(A–C) For 24 hours, 661W cells were treated with cytokines (CK; 20 ng/mL). (A) Protein tyrosine phosphatase 1B mRNA levels were determined by
real-time PCR. Used as a control was 18S RNA. Results are expressed as 2DCt. (B) Protein extracts (50 lg) were separated by SDS-PAGE and analyzed by
Western blot with the anti-PTP1B antibody (Ref. 05-1087; Millipore). Alpha-tubulin was used as a loading control. Representative autoradiograms are
shown. (C) Protein tyrosine phosphatase 1B enzymatic activity was analyzed as described in Materials and Methods. The results of PTP1B enzymatic
activity are expressed as picomoles of released phosphate/min/g protein. The results are means 6 SEM (n¼ 5 independent experiments). Data were
analyzed by Student’s paired t-test; *P  0.05 cytokines (CK) versus nonstimulated basal (B). Retinal explants were treated with cytokines (CK; 20 ng/
mL) for 24 hours. (D) Protein tyrosine phosphatase 1B mRNA levels were determined by real-time PCR. Used as a control was 18S RNA. Results are
expressed as 2DCt. (E) Protein extracts (50 lg) were separated by SDS-PAGE and analyzed by Western blot with the anti-PTP1B antibody (Ref. 05-1087;
Millipore). Alpha-tubulin was used as a loading control. The results are expressed as fold change and are means 6 SEM (n¼12 independent retinas per
condition). Data were analyzed by Student’s paired t-test. Comparisons were *P  0.05 cytokines (CK) versus nonstimulated basal (B).
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FIGURE 5. Reduction of PTP1B levels by siRNA in retinal cells protected against inflammation-mediated inhibition of IGF-IR signaling. (A) Efficiency
of PTP1B siRNA in decreasing PTP1B levels in 661W cells. (B, C) For 36 hours, 661W cells were transfected with scrambled or PTP1B siRNA
oligonucleotides and transfected cells were treated with cytokines (CK; 20 ng/mL) for 24 hours, serum-starved for 2 hours and further stimulated
with IGF-I (10 nM) for 15 minutes. (D) Efficiency of PTP1B siRNA in decreasing PTP1B in retinal explants. (E, F) Retinal explants were treated with
siRNAs and stimulated as described for 661W cells. (G) Retinal explants from PTP1B/ mice were stimulated with cytokines and IGF-I as indicated
above. Protein extracts (50 lg) were separated by SDS-PAGE and analyzed by Western blot with the corresponding antibodies: anti-PTP1B (Ref. 07-
088; Millipore), anti-phospho IGF-IR (Tyr 1135/1136), anti-IGF-IR, anti-phospho Akt (Ser473), anti-Akt, and anti–a-tubulin. Representative
autoradiograms are shown (n¼ 5 independent experiments or retinas per experimental condition). Autoradiograms were quantitated by scanning
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was 13.3-fold higher than the response of this condition in the
scrambled siRNA treatment (CKI siRNA PTP1B versus CKI SC).
To reinforce data obtained with siRNA in a genetic modified
mouse model, we prepared retinal explants from PTP1B-
deficient mice (PTP1B/) as previously reported.26 Interest-
ingly, the treatment with cytokines did not reduce the
response to IGF-I regarding Akt phosphorylation in retinas
from PTP1B/ mice (Fig. 5G).
We did not detect cell death in either 661W cells or retinal
explants transfected with siRNA (results not shown).
Pharmacologic Inhibition of PTP1B Reduced
Reactive Gliosis in Retinal Explants Treated With
Cytokines
Neurodegenerative diseases of the retina, including AMD, DR,
and glaucoma involve chronic and dysregulated neuroinflam-
mation and reactive gliosis.42,43 To get insight into the benefit
of PTP1B inhibition in the whole retina under proinflammatory
conditions, we evaluated the effect of cytokines on reactive
gliosis in the ex vivo model of mouse retinal explants.
Treatment with cytokines for 24 hours increased GFAP
expression analyzed by Western blot by 4.5-fold (Fig. 6A) and
also increased GFAP staining (10-fold) in live retinal explants
(Fig. 6B) indicating that, in the retina, cytokine-mediated
reactive gliosis concurred with disruption of the IGF-IR–
mediated signaling cascade. We also analyzed the effect of
pharmacologic inhibition of PTP1B in reactive gliosis. Cotreat-
ment with cytokines and the PTP1B inhibitor used at 10 lM as
described44 decreased by 2-fold GFAP protein levels in mouse
retinal explants (Fig. 6A).
Pharmacologic Inhibition of PTP1B Reduced
Reactive Gliosis in Retinal Explants From db/db
Mice
It has been reported that diabetic db/db mice presented
systemic inflammation45 and reactive gliosis in the retina.3 On
that basis, we analyzed PTP1B expression in retinas of these
mice. Protein tyrosine phosphatase 1B mRNA and protein
levels were increased by 1.8- and 3-fold, respectively, in retinas
from db/db mice compared with the lean db/þ controls (Figs.
7A, 7B). Finally, we evaluated the efficacy of the PTP1B
inhibitor against the reactive gliosis of db/db mice.3 As
depicted in Figure 7C, GFAP immunostaining was decreased
by 0.4-fold in retinal explants from db/db mice cultured with
the PTP1B inhibitor for 24 hours.
DISCUSSION
In chronic diseases of the retina linked to neuroinflammation,
retinal macroglia, and microglia populations demonstrate
activation and gliosis,46,47 which contribute to neurodegener-
ation in the neighbor retinal cells and, ultimately, in vision
loss.4,48 Thus, unravelling the molecular mechanisms that
confer protection to retinal cells against chronic neuro-
inflammation, as well as elucidating their therapeutic modula-
tion, is of key importance. So far, current treatments for DR are
applicable only at advanced stages and are associated with
adverse effects. Therefore, new pharmacologic treatments
aimed to combat retinal neuroinflammation associated to DR
are urgently needed. This study provides evidence of the
beneficial effect of targeting PTP1B in the retina in the IGF-IR/
Akt survival signaling pathway and reactive gliosis.
Although IGF-I has been recognized for its peripheral
effects in growth and metabolism, it has a role in the CNS as a
neurotrophic peptide triggering prosurvival signaling path-
ways responsible for activation of antiapoptotic cascades,
enhancement of nerve growth, and promotion of synaptic
plasticity.49 Moreover, IGF-IR signaling reduces neuroinflam-
mation-dependent sensitivity of neurons to the proparkinso-
nian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP).50 In the retina, early intervention with systemic IGF-I
in diabetic rats inhibits neuroretinal cell death.51 However, at
the molecular level the impact of the chronic inflammatory
environment, which is present in the retina in insulin
resistance and T2DM,52 in the IGF-IR signaling in retinal cells
has not been investigated in depth. Taking into account these
previous findings, this study has identified for the first time a
negative cross-talk between signaling pathways activated by
the proinflammatory milieu and the IGF-IR/Akt neuroprotec-
tive pathway in photoreceptors that are major contributors to
diabetes-induced local inflammation in the retina.53,54 We
found that 661W cells are direct targets of proinflammatory
cytokines as manifested by a rapid phosphorylation of JNK
and p38 MAPK similar to that of peripheral cells during
obesity.40,55,56 Because a previous report described that
activation of JNK in response to light preceded apoptosis in
661W cells,57 our results suggest that under conditions in
which chronic inflammation reaches the retina, activation of
stress kinases occur as it does in peripheral insulin-sensitive
cells. In this regard, the feedback mechanism mediated by
JNK responsible of the early phosphorylation of IRS1 at serine
307 that targets it for proteasomal degradation35 was found in
photoreceptors and retinal explants cultured with proin-
flammatory cytokines. We have successfully used retinal
organotypic cultures to characterize pathologic cell death
during retinal degeneration.58 Herein, we made use of these
cultures for elucidating the signaling pathways deregulated in
DR. Considering these previous findings, long-term (24 hours)
exposure of retinal cells and retinal explants to cytokines
decreased IGF-IR tyrosine phosphorylation in response to
IGF-I and triggered the degradation of IRS1. Intriguing,
increased Akt phosphorylation was found in retinal explants
treated with cytokines. This might result of compensatory
mechanisms that could alter the expression or activity of
specific serine phosphatases attempting to counteract the
deleterious effects of cytokines. Nevertheless, under these
conditions IGF-I was not able to further increase Akt
phosphorylation, reflecting the profound IGF-I resistance
induced by the proinflammatory milieu. Altogether, our
results suggest a negative cross-talk between signaling
pathways triggered by proinflammatory cytokines and IGF-
IR–mediated signaling in the retina at the level of IGF-IR and
IRS1 that constitute a critical node of modulation of the
insulin/IGF-I signaling network.12 This negative cross-talk was
directly reflected by decreased Akt phosphorylation. Because
densitometry. Levels of phosphorylated proteins (pIGF-IR and pAkt) were normalized by levels of corresponding total (IGF-IR and Akt) proteins that
were used as loading controls. These results are expressed as fold change of IGF-I stimulation related to each basal. Levels of PTP1B were normalized
by a-tubulin. The results are means 6 SEM. In (A) and (D), data were analyzed by paired t-test and comparisons were *P  0.05 siRNA PTP1B versus
scrambled siRNA (SC). In (C) and (F), data were analyzed by 1- or 2-way ANOVA followed by Bonferroni t-test. Comparisons were *P  0.05 CKI
siRNA PTP1B versus CKI SC.
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it has been demonstrated that the neuroprotective action of
IGF-I in vivo is most likely mediated by the PI 3-kinase/Akt
pathway,59 our data strongly suggest that the proinflamma-
tory milieu in the retina might compromise the fate of retinal
cells.
Protein tyrosine phosphatase 1B has emerged as a negative
modulator of IR/IGF-IR tyrosine phosphorylation but most
studies have focused on its role in inflammation linked to
obesity and T2DM.39 In the retina, Rajala and coworkers60
demonstrated a negative modulation of IR tyrosine phosphor-
ylation by PTP1B in diabetic mice and, conversely, enhanced IR
phosphorylation in rod photoreceptors from PTP1B-deficient
mice under light stress.25 As reported in fibroblasts,21 we have
demonstrated that PTP1B modulates IGF-IR tyrosine phosphor-
ylation in the retina.26 Thus, all these evidences prompted us
to investigate the role of PTP1B in the retina under
proinflammatory conditions. In 661W cells treated with
proinflammatory cytokines both PTP1B mRNA protein levels
and its enzymatic activity were elevated and this effect was also
reflected in the whole retina. Interestingly, treatment of 661W
cells with cytokines induced a cleavage of PTP1B similar to that
reported in platelets that resulted in increased enzymatic
activity.38
Based on our previous work in which PTP1B deficiency
enhanced the IGF-IR/Akt-mediated signaling in mouse retina,26
we used PTP1B siRNA to transiently decrease PTP1B in retinal
cells and avoid constitutive adaptations of genetic deletion.
This approach allowed us to maintain IGF-I responsiveness of
FIGURE 6. Pharmacologic inhibition of PTP1B reduced reactive gliosis induced by proinflammatory cytokines in retinal explants. Whole retinas
were obtained from 10-week-old mice and cultured with cytokines (CK; 20 ng/mL) for 24 hours in the presence or absence of the PTP1B inhibitor
(10 lM). (A) Protein extracts (50 lg) were separated by SDS-PAGE and analyzed by Western blot with the corresponding antibodies against GFAP
and a-tubulin that was used as a loading control. Representative autoradiograms are shown. Autoradiograms corresponding to GFAP levels were
quantitated by scanning densitometry. The results are means 6 SEM (n ¼ 5 retinas per experimental condition). Data were analyzed by 1-way
ANOVA followed by Bonferroni t-test. Comparisons were *P  0.05 cytokines (CK) versus basal (B); †P  0.05 CK plus PTP1B inhibitor versus CK.
(B) Whole retinas were obtained from 10-week-old mice, cultured as described in (A) an immunostaining for GFAP (green) was carried out. Five
retinas per experimental condition were analyzed. Representative confocal images are shown. Quantification of immunofluorescence was
performed as described in Methods. Data were analyzed by paired t-test. Comparisons were *P  0.05 CK versus basal (B).
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FIGURE 7. Pharmacologic inhibition of PTP1B reduced reactive gliosis in db/db mice. Whole retinas were obtained from 10-week-old db/þ and db/
db mice. (A) Protein tyrosine phosphatase 1B mRNA levels were determined by real-time PCR. As a control, 18S RNA was used. Results are
expressed as 2DCt. (B) Protein extracts (50 lg) were separated by SDS-PAGE and analyzed by Western blot with the anti-PTP1B antibody (Ref. 05-
1087; Millipore). Alpha-tubulin was used as a loading control. Representative autoradiograms are shown. The results are means 6 SEM (n ¼ 12
independent retinas per condition). Data were analyzed by Student’s paired t-test. Comparisons were *P  0.05 db/db versus db/þ. (C)
Immunostaining for GFAP (green) was carried out in retinas from db/þ and db/db mice (upper panels) and in retinas from db/db mice were
cultured for 24 hours in the presence or absence of the PTP1B inhibitor (10 lM; lower panels). Five retinas per experimental condition were
analyzed. Representative images are shown. Quantification of immunofluorescence was performed as described in Methods. Data were analyzed by
paired t-test. Comparisons were *P  0.05 db/db versus db/þ and †P  0.05 db/db PTP1B inhibitor versus db/db basal.
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661W cells in the presence of proinflammatory cytokines as
reflected by increased levels of IGF-IR and Akt phosphorylation
compared with the scrambled condition. The pathophysiolog-
ical relevance of these results was assessed in retinal explants
in which we were able to reduce PTP1B levels by siRNA and
recover IGF-IR/Akt sensitization in a proinflammatory environ-
ment as in the retinas from PTP1B/ mice. We previously
reported that PTP1B deficiency rescued IGF-IR tyrosine
phosphorylation, but not Akt phosphorylation, in retinas from
diabetic IRS2-deficient mice due to elevated PTEN levels.26
However, results presented herein indicate that PTP1B
silencing maintained IGF-IR–mediated Akt phosphorylation in
the presence of an inflammatory environment. An explanation
for these differences could be the lack of effect of proin-
flammatory cytokines in modulating PTEN in retinal cells and
explants (data not shown), suggesting the importance of this
inositol phosphatase in blocking the pathway specifically
upstream of Akt.
Insulin/IGF-I resistance links obesity and/or T2DM to
neurodegeneration, which has far-reaching effects in the
CNS.6,61 In fact, both peripheral and central insulin resistance
may be boosted by the chronic inflammatory environment
associated with obesity. On the other hand, low serum IGF-I
input to the brain may also exacerbate gliosis as IGF-I is
involved in the inflammatory responses of glial cells.62 In this
regard, our study has shown for the first time that a
combination of proinflammatory cytokines is sufficient to
induce reactive gliosis, monitored by levels of GAFP, in the
retina and this effect is ameliorated by cotreatment with a
PTP1B inhibitor, which might act by enhancing IGF-IR–
mediated signaling as occurred in the insulin signaling.44
Although deleterious effects of high levels of IGF-I in the retina
have been reported,63–65 our previous data in retinal explants
from mice with retinitis pigmentosa that presented hallmarks
of inflammation, showed that treatment with IGF-I for 24 hours
ameliorated reactive gliosis.66 A step further, PTP1B expression
was elevated in the retina of diabetic db/db mice that showed
systemic inflammation45 and reactive gliosis3 reinforcing the
link between PTP1B and inflammation in the retina. Interest-
ingly, reactive gliosis in retinal explants from db/db mice was
reduced by treatment with a PTP1B inhibitor. As reactive
gliosis is present in DR,3,67–69 our results might have
therapeutic implications proposing a novel strategy for its
treatment based on the specific inhibition of PTP1B in the
retina.
In conclusion, our results show that retinal cells respond
to the proinflammatory environment triggering signaling
cascades that interfere with the IGF-IR/Akt survival pathway
and induce reactive gliosis. These effects can be prevented
by reducing PTP1B levels and strongly suggest that targeting
this phosphatase might be useful for modulating the
beneficial effects of IGF-I in the inflammatory states during
DR.
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